Press release
Illumina and NVIDIA collaborate to decode biology and propel precision health
Collaboration combines Illumina's sequencing technologies and Illumina Connected Software with NVIDIA tools to develop biological foundation models SAN DIEGO,
About this update from Illumina, Inc.
[{"type":"text","content":"Collaboration combines Illumina's sequencing technologies and Illumina Connected Software with NVIDIA tools to develop biological foundation models\nSAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in clinical research, genomics AI development, and drug discovery.\n\nTo optimize analysis of the vast amounts of data involved in multiomic research, Illumina and NVIDIA will combine advancements in AI with multiomic data at scale. Leveraging Illumina's leading sequencing technology and informatics tools alongside NVIDIA's leading AI technology, the partnership aims to accelerate drug discovery and clinical development, delivering powerful tools to help pharmaceutical companies identify new and better drug targets.\nIllumina's leading sequencing technology—as well as its menu of DRAGEN-powered multiomics offerings, genomics AI tools, and Illumina Connected Analytics platform—has streamlined genomic data generation and analysis. Illumina has invested in AI for genomic interpretation, developing the leading SpliceAI, PrimateAI-3D, and Emedgene xAI algorithms.\nNow, in addition to its own efforts, Illumina will look to expand its customer offerings with models developed by the NVIDIA Biology Foundation Model Research Team and partners. Customers will also be able to leverage these models with their own proprietary datasets to improve the performance for biologically relevant tasks of interest, such as cell state or gene transcription prediction.\nWith this new partnership, the global R&D community can tap into rich genomic data by integrating NVIDIA RAPIDS™ accelerated data science software with the NVIDIA BioNeMo™ platform's generative AI models and fine-tuning capabilities for proprietary datasets, as well as MONAI for spatial cell imaging workflows. Illumina and NVIDIA will work to make these tools accessible on the Illumina Connected Analytics platform.\n\"Over the past 20 years, Illumina has democratized sequencing, and with the progress in AI and multiomic analysis, we are enabling customers to derive novel insights for their applications,\" said Rami Mehio, head of global software and informatics at Il...